{"name":"NovaBay Pharmaceuticals","slug":"novabay","ticker":"NBY","exchange":"NYSE American","domain":"novabay.com","description":"NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis","hq":"Emeryville, CA","founded":0,"employees":"","ceo":"Justin Hall","sector":"Specialty Pharma — Ophthalmology / Dermatology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$12M","metrics":{"revenue":10200000,"revenueGrowth":-99.4,"grossMargin":0,"rdSpend":42000,"netIncome":-22141000,"cash":9035000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2014"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"NeutroPhase patent cliff ($10.0M at risk)","drug":"NeutroPhase","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Auriclosene Solution 0.3%","genericName":"Auriclosene Solution 0.3%","slug":"auriclosene-solution-0-3","indication":"Other","status":"phase_2"},{"name":"NVC-422, 0.2%","genericName":"NVC-422, 0.2%","slug":"nvc-422-0-2","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Auriclosene Irrigation Solution, 0.2%","genericName":"Auriclosene Irrigation Solution, 0.2%","slug":"auriclosene-irrigation-solution-0-2","indication":"Treatment of mild to moderate diabetic foot ulcers","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Experimental: CD07223 1.5% Topical Gel TID","genericName":"Experimental: CD07223 1.5% Topical Gel TID","slug":"experimental-cd07223-1-5-topical-gel-tid","indication":"Treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)","status":"phase_2"}]}],"pipeline":[{"name":"Auriclosene Irrigation Solution, 0.2%","genericName":"Auriclosene Irrigation Solution, 0.2%","slug":"auriclosene-irrigation-solution-0-2","phase":"phase_2","mechanism":"Auriclosene Irrigation Solution is a topical antimicrobial agent that kills bacteria and fungi by disrupting their cell membranes.","indications":["Treatment of mild to moderate diabetic foot ulcers"],"catalyst":""},{"name":"Auriclosene Solution 0.3%","genericName":"Auriclosene Solution 0.3%","slug":"auriclosene-solution-0-3","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Experimental: CD07223 1.5% Topical Gel TID","genericName":"Experimental: CD07223 1.5% Topical Gel TID","slug":"experimental-cd07223-1-5-topical-gel-tid","phase":"phase_2","mechanism":"CD07223 is an experimental drug that targets the bacterial cell wall synthesis pathway.","indications":["Treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)"],"catalyst":""},{"name":"NVC-422, 0.2%","genericName":"NVC-422, 0.2%","slug":"nvc-422-0-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-27","type":"earnings","headline":"NovaBay Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"NovaBay Pharmaceuticals reported its fourth quarter and full year 2022 financial results, with revenue of $1.4 million and a net loss of $4.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"NovaBay Pharmaceuticals Announces Exclusive Distribution Agreement with Medimetriks Pharmaceuticals","summary":"NovaBay Pharmaceuticals announced an exclusive distribution agreement with Medimetriks Pharmaceuticals for its NeutroPhase product.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOa05VZ1RGb3ZwLWpqNDBfZ2lsdkoyNGFUVjNNUFJVVXZ3b1o2RkhHVGN6NkVEU0dGWGI0YWQ5UnB6U1N0WUo2dk5kZU9TZmJVOFhibW9sY1k2cGwtVjJvdUh5NmllNUc5ZmRvQ1pTSnl6TmdKbVNnVHZtVzFXTWJYZ2MzRFotNVhrQWhNbWdnMmhiVnp6RnRuR0dGc3UyeUJoTkZrbXRGa3VjbGc?oc=5","date":"2026-03-24","type":"pipeline","source":"Benzinga","summary":"NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19% - Benzinga","headline":"NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOM2RwRWEwT3RsbkRSOElhY2tSYU01Y09NMjQ2djhYSTFUeERvam9ZdFB2Z1JfVlZRY205WThZN3RaVHBQMW1lU3dyYW1HckxKTTlzenpaVHAxdkFYcVlJXzBjeGhGanVwTWdqdkl6c0VTMk1ERDVPX09FMUd3TlRiWWZpdUIxLXNHMUluTGVwT0JMS0N0cU5aRmlnQVVvc3VYajFleWV1dHh3cVBfaUEzTnExTFRIOGpy?oc=5","date":"2026-03-23","type":"pipeline","source":"CoinDesk","summary":"NovaBay Pharmaceutical (NBY) pivoting to crypto - CoinDesk","headline":"NovaBay Pharmaceutical (NBY) pivoting to crypto","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPNTNBYTdRR0hUdTR0YUFZZ2xEaDA5ay1ZOWIxZnVjLVFONjlkMDZsWE43WVg5d1RSRmZwTkdNV0d0a19WMEd0MldDZVJrOHhzVmRyb2ZSZGswbGFqbFFJTDRiMUxPUU1JYmgxUXBiQ284QmV1OUEzTlRrN1pMOHdCUzVla3pmNjk5YWZGb1hYcnFwa1Z0?oc=5","date":"2026-03-23","type":"pipeline","source":"thestreet.com","summary":"Pharmaceutical stock surges 26% after crypto pivot - thestreet.com","headline":"Pharmaceutical stock surges 26% after crypto pivot","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFByUFVrVm9HS1M1VDlacGhYdDlzeC1BTV9zbDRwVkRpcHQ2eDV6d0RVQmREYlowdGJQYzc2SnlVU283cWx6OGJXNVc0WHEzYjd4aURSeklqVmhjaUFRX2ltb19MN3k3S190MWpfdw?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Novabay Pharma (NBY) - Stock Titan","headline":"If You Invested $1,000 in Novabay Pharma (NBY)","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQVjVuMUpnbVRzQWVhYjRFejNEdjZhRWVVeG5XdGx3dVEtMjE4eWg2ZDBJdmJhbW9DTzNHLXd1OFNwYTRHaWw1bXJ2T2NYQjIwemFsS0oxeUtTSXN4ejhVYVlUek5TaGh3LVBlcVNPWDE1RjdIYVZQWjFhWXgyWmFfYURfMEpNZ05UVGE2RE1nNjdEZ2pGREJFNUtxWnJHdzdleVpJempYdU5LZnQzbUYwcmNvUk9UZw?oc=5","date":"2026-03-12","type":"pipeline","source":"TipRanks","summary":"NovaBay Pharma Expands Share Capital and Governance Flexibility - TipRanks","headline":"NovaBay Pharma Expands Share Capital and Governance Flexibility","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQNWFTeExqWnJHcmgwaVVlT1pHT0FsRExhUFBqdFpHdWVFU3NjcWxVNG9wQWhtMHpkSHhqOUEtQVdfQjh6OTVKWXBsWG03cU1mbW00ZDdSVEE5TFV2LUs0bXlHZ00zNUsxaUlJR0V6a2xhQmJxc2t4VV9UUzJHZHRCVk5uSWRkSko5WnVHaFhBLWgxU2JHc29KMGhFSkFNdTVuMjJPNVlzNU5Ra3lLeHhUZi0zYkpzdE0?oc=5","date":"2026-02-11","type":"pipeline","source":"Stock Titan","summary":"Reverse split shrinks NovaBay (NYSE: NBY) share count fivefold - Stock Titan","headline":"Reverse split shrinks NovaBay (NYSE: NBY) share count fivefold","sentiment":"neutral"},{"date":"2026-01-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"NeutroPhase","drugSlug":"neutrophil-activating-peptide-1","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":10000000}],"drugCount":4,"phaseCounts":{"phase_2":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Bausch Health","Johnson & Johnson"],"therapeuticFocus":["Ophthalmology","Dermatology"],"financials":{"source":"sec_edgar+yahoo","revenue":370000,"revenuePeriod":"2014-12-31","revenueHistory":[{"value":370000,"period":"2014-12-31"},{"value":60812000,"period":"2013-12-31"},{"value":3254000,"period":"2013-12-31"},{"value":3254000,"period":"2013-12-31"},{"value":57572000,"period":"2012-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":42000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22141000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":9035000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}